Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of the mitochondrial genome. First identified in 2001 during a screen for factors that protect neurons against amyloid-beta toxicity, humanin has since been recognized as a broad-spectrum cytoprotective peptide with relevance far beyond neurodegeneration — extending to cardiovascular protection, metabolic regulation, and cellular stress resistance.

Humanin belongs to a family of mitochondrial-derived peptides that includes MOTS-c and SHLPs (small humanin-like peptides), all encoded within mitochondrial DNA. This family represents a recently discovered axis of mitochondrial signaling — the mitochondria not only produce energy but also generate peptide signals that communicate cellular stress status and activate protective pathways throughout the body.

Endogenous humanin levels decline with age, correlating with the progressive mitochondrial dysfunction that characterizes aging. This decline is associated with increased vulnerability to Alzheimer's disease, cardiovascular disease, and metabolic dysfunction. The therapeutic rationale is to supplement declining endogenous levels with exogenous humanin to restore mitochondrial-protective signaling.

Most humanin research to date is preclinical, conducted in cell culture and animal models. Limited human observational data links higher circulating humanin levels with better metabolic health and longevity, but controlled human intervention trials remain scarce. This protocol synthesizes available evidence and practitioner experience, with the understanding that clinical proof of efficacy in humans is still developing.

Dose selection

Standard dose range: 1-5 mg per day, subcutaneously.

Research has used various humanin analogs, most commonly HNG (humanin S14G), a single amino acid substitution that increases potency approximately 1000-fold compared to native humanin. If using HNG, doses in the microgram range (50-200 mcg) may be appropriate. If using native-sequence humanin, milligram dosing is typically required.

Starting dose: Begin at the lower end of the applicable range — 1 mg for native humanin or 50 mcg for HNG — for the first 1-2 weeks to assess tolerability.

Titration: Increase to the mid-range dose (2-3 mg native humanin or 100 mcg HNG) after 2 weeks if tolerated without adverse effects. Further increases to the upper range should be guided by response and biomarker data rather than arbitrary escalation.

Important: Confirm which humanin form is being used before dosing. The potency difference between native humanin and the HNG analog is substantial, and applying native-sequence doses to the HNG analog would result in a massive overdose. Supplier documentation should specify the exact sequence.

Timing and administration

Route: Subcutaneous injection. Humanin is a peptide and is subject to gastrointestinal degradation, making oral administration ineffective at practical doses.

Timing: Morning administration is the most common approach, aligning with the diurnal rhythm of mitochondrial bioenergetic demand. Some practitioners recommend splitting the dose between morning and evening to maintain more consistent circulating levels, though no comparative data establishes the superiority of either approach.

Fasting requirements: No established requirements. Humanin acts through systemic circulation and intracellular signaling pathways that are not meaningfully affected by gastrointestinal contents. Administering at a consistent time each day is more important than timing relative to meals.

Injection site: Standard subcutaneous sites — abdomen, upper thigh, or deltoid area. Rotate sites as with any daily injection protocol.

Reconstitution and storage: Reconstitute lyophilized humanin with bacteriostatic water. Store refrigerated at 2-8 degrees Celsius. Use within 4 weeks of reconstitution. Humanin is a relatively stable peptide, but standard cold-chain practices apply.

Cycle structure

Standard cycle: 8-12 weeks on, 4 weeks off.

The rationale for the longer active phase compared to many peptide protocols reflects humanin's mechanism. Unlike peptides that stimulate receptor-mediated responses where tolerance can develop quickly, humanin functions as a cytoprotective signal — it does not drive the cell to produce more of something, but rather protects existing cellular machinery from damage. This mode of action is less susceptible to receptor desensitization.

Off-period purpose: The off-period allows assessment of whether the protective effects persist beyond the period of active supplementation (suggesting structural mitochondrial improvements have been achieved) or rapidly diminish (suggesting ongoing supplementation is needed to maintain benefit). It also provides a safety window for detecting any delayed adverse effects.

Long-term cycling: For ongoing mitochondrial support, a pattern of 12 weeks on, 4 weeks off can be repeated. Reassess biomarkers at the end of each active phase and compare to the initial baseline. If mitochondrial function markers have plateaued, a longer off-period (8 weeks) may be appropriate before the next cycle.

Monitoring

Mitochondrial function markers:

Lactate-to-pyruvate ratio (elevated ratio indicates impaired mitochondrial oxidative phosphorylation and reliance on anaerobic glycolysis)
Coenzyme Q10 levels (CoQ10 is a critical component of the electron transport chain; levels reflect mitochondrial density and function)
Organic acids panel (urinary organic acids can reveal patterns consistent with mitochondrial dysfunction — elevated succinate, fumarate, and citrate)
GDF-15 (growth differentiation factor 15) — a stress-response biomarker that is elevated in mitochondrial dysfunction and declines as mitochondrial health improves

Cardiometabolic markers:

Fasting glucose and insulin (humanin improves insulin sensitivity in preclinical models)
HbA1c for longer-term glycemic trends
Lipid panel with focus on triglycerides and HDL (humanin has demonstrated lipid-modulatory effects in animal studies)
hs-CRP as a broad inflammatory marker

Neuroprotective assessment: For individuals using humanin specifically for cognitive or neuroprotective purposes, baseline and follow-up cognitive assessments (even simple validated tools like the Montreal Cognitive Assessment) provide useful data points. Amyloid-beta and phospho-tau biomarkers are research-grade assessments not widely available but represent the most direct measures of the neuroprotective effects humanin is hypothesized to provide.

Subjective markers: Energy levels, exercise recovery, cold tolerance (mitochondrial thermogenesis), cognitive clarity, and overall sense of resilience. These are downstream indicators of mitochondrial health improvements and should be tracked with a simple daily log.

Common combinations

Humanin + MOTS-c (5-10 mg subcutaneously, 3-5 times per week): This is the flagship mitochondrial peptide combination. Humanin and MOTS-c are both mitochondrial-derived peptides but act through different mechanisms — humanin is primarily cytoprotective (preventing mitochondrial damage and apoptosis), while MOTS-c is primarily metabolic (activating AMPK, improving insulin sensitivity, and promoting mitochondrial biogenesis). Together, they protect existing mitochondria while simultaneously stimulating the production of new, healthy mitochondria. This combination addresses both sides of the mitochondrial health equation.

Humanin + SS-31 (Elamipretide, 0.5-1 mg subcutaneously daily): SS-31 is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane, where it stabilizes cardiolipin — a phospholipid essential for electron transport chain complex organization and efficiency. While humanin provides broad cytoprotective signaling, SS-31 provides targeted structural support to the mitochondrial inner membrane. This combination is particularly relevant for individuals with cardiovascular concerns, as both peptides have demonstrated cardioprotective effects in preclinical models.

Humanin + NAD+ precursors (NMN 500-1000 mg or NR 300-600 mg daily): NAD+ is a critical cofactor for mitochondrial enzymes, and its levels decline with age in parallel with humanin. Supplementing both addresses the energetic substrate (NAD+) and the protective signaling (humanin) simultaneously.

Humanin + CoQ10 (200-400 mg ubiquinol form daily): CoQ10 is a direct electron carrier in the mitochondrial electron transport chain. As both a supplement and a monitoring biomarker, CoQ10 complements humanin by directly supporting the bioenergetic machinery that humanin protects.

Contraindications and cautions

Active cancer: Humanin's anti-apoptotic properties are beneficial in healthy aging tissue but theoretically could protect malignant cells from programmed death. While preclinical data on this question is mixed — some studies suggest humanin may have context-dependent effects — active malignancy represents a clear contraindication until this issue is resolved through dedicated research.

Pregnancy and breastfeeding: Insufficient safety data. Mitochondrial-derived peptides play roles in embryonic development, and exogenous supplementation could have unpredictable effects on fetal mitochondrial signaling.

Individuals on metformin or other AMPK activators: MOTS-c (a common combination partner) also activates AMPK. If combining humanin with MOTS-c in individuals already taking metformin, monitor blood glucose closely — additive AMPK activation could increase the risk of hypoglycemia, particularly in non-diabetic individuals.

Autoimmune conditions: Humanin modulates inflammatory signaling. While generally anti-inflammatory, any immunomodulatory peptide should be used cautiously in individuals with active autoimmune conditions, ideally under physician supervision.

Expected timeline

Weeks 1-2: Minimal subjective changes expected. This is the adaptation and tissue-saturation phase. Some individuals report subtle improvements in energy or mood, but these early effects are unreliable indicators of long-term response.

Weeks 3-6: Gradual improvements in energy levels, exercise recovery, and potentially cognitive clarity should begin to emerge in responders. These effects are subtle — humanin does not produce the dramatic, acute effects of a growth hormone secretagogue or nootropic stimulant. The benefits reflect incremental improvements in mitochondrial efficiency across billions of cells.

Weeks 6-12: Biomarker changes should become measurable — improvements in lactate-to-pyruvate ratio, GDF-15 trends, and potentially fasting insulin sensitivity. Subjective benefits should be more clearly established and distinguishable from placebo.

Post-cycle assessment: During the off-period, monitor which benefits persist (suggesting structural mitochondrial improvements) and which fade (suggesting ongoing supplementation is needed). This information guides the structure of subsequent cycles.